FIGURE 1.

Characteristics of selected patients with breast cancer for generation of patient‐specific induced pluripotent stem cell‐derived cardiomyocytes. (A) Flow diagram of patient selection. Twenty‐four of 468 patients with breast cancer (5.1%) who received trastuzumab (Tmab)‐based treatment were diagnosed with cancer therapy‐related cardiac dysfunction (CTRCD). Three patients in each group were selected from the severely cardiotoxic patient group (SP), patients with a reduced left ventricular ejection fraction (LVEF) of at least 30% from baseline. (B) Time series of LVEF in the six patients. Cardiac‐function values within the yellow background indicate that Tmab could not be administered. NP, patients without cardiotoxicity